Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Various Advanced Cancer Clinical Trial

Official title:

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01986218
• Other study ID #: CA002-001
• Status: Terminated
• Phase: Phase 1
• First received: November 11, 2013
• Last updated: September 13, 2016
• Start date: November 2013
• Est. completion date: March 2016

Study information

• Verified date: September 2016
• Source: Bristol-Myers Squibb
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health CanadaAustralia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety and effectiveness of daily doses of BMS-986115 in subjects with advanced solid tumors

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 36
• Est. completion date: March 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Subjects with a histologically or cytologically confirmed diagnosis of solid tumors, advanced or metastatic, refractory to or relapsed from standard therapies or for which there is no known effective treatment

• Life expectancy of at least 3 months

• Eastern Cooperative Oncology Group (ECOG) performance status score 0-1

• Prior anti-cancer treatments are permitted (i.e., chemotherapy, radiotherapy, hormonal, or immunotherapy)

• At least 4 weeks must have elapsed from last dose of prior anti-cancer therapy and the initiation of study therapy

Exclusion Criteria:

• Subjects with known or suspected brain metastases, primary brain tumors, or brain as the only site of disease

• Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy = 7 days prior to administration of study medication

• Current or recent (within 3 months of study drug administration) gastrointestinal disease such as chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease. Non-chronic conditions (e.g. infectious diarrhea) that are completely resolved for at least 2 weeks prior to starting study treatment are not exclusionary

• Any major surgery or gastrointestinal disease that would interfere with administration of oral medications

• Conditions requiring chronic systemic glucocorticoid use, such as autoimmune disease or severe asthma, excluding inhalation steroids for maintenance.

• Uncontrolled or significant cardiovascular disease

• History of medically significant thromboembolic events or bleeding diathesis within the past 6 months

• Inadequate bone marrow function (Absolute neutrophil count (ANC) < 1,500 cells/mm3; Platelet count < 100,000 cells/mm3; Hemoglobin < 9.0 g/dL)

• Inadequate hepatic function (Total bilirubin > 1.5 times the institutional upper limit of normal (ULN) (except known Gilbert's syndrome); Alanine transaminase (ALT) or aspartate transaminase (AST) > 2.5 times the institutional ULN. ALT or AST up to 3 times the institutional ULN permitted if total bilirubin is normal

• Uncontrolled (= Grade 2) hypertriglyceridemia (fasting triglycerides > 300 mg/dL (3.42 mmol/L))

• Inadequate renal function (Blood creatinine > 1.5 times the institutional ULN)

• Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus (HIV) -1, -2 antibody

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Various Advanced Cancer

Intervention

Drug:
• BMS-986115

Locations

Country	Name	City	State
Australia	Local Institution	Parkville	Victoria
Canada	Local Institution	Toronto	Ontario
Canada	Local Institution	Vancouver	British Columbia
United States	Usc/Norris Comprehensive Cancer Center	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of multiple daily doses of BMS-986115	Measured by the frequency of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, Grade 3 or 4 AEs, deaths, laboratory abnormalities and clinically relevant electrocardiogram (ECG) changes from baseline	Up to 30 days after the last dose of study medication (approximately 18 months)	Yes
Secondary	Maximum observed plasma concentration (Cmax) of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Time of maximum observed plasma concentration (Tmax) of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Trough observed plasma concentration (Ctrough) of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Terminal plasma half-life (T-HALF) of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Apparent total body clearance (CLT/F) of BMS-986115		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Apparent volume of distribution at steady-state (Vz/F) of BMS-986115		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986115		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Ratio of metabolite AUC(INF) to parent AUC(INF) after single dose and ratio of metabolite AUC(TAU) to parent AUC(TAU) at steady state, corrected for molecular weight (MR_AUC) of BMS-986115 and its active metabolite BMT-100948		29 timepoints up to Cycle 3 Day 1 (approximately 32 days)	No
Secondary	Pharmacodynamics (PD) changes in the expression of Notch pathway-related genes, including but not limited to Hes1 and Deltex1, as determined by standard molecular methods		16 timepoints up to Cycle 2 Day 16 (approximately 20 days)	No
Secondary	Preliminary anti-tumor activity of BMS-986115 as measured by response evaluation criteria in solid tumors (RECIST)	Assessed by: Tumor Response based on the Investigator's assessment using RECIST v1.1 [categorized as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD)]; Best Overall Response (BOR), defined as the best tumor response recorded between the data of first dose and the last on-study tumor assessment (prior to any subsequent cancer therapy); Overall Response Rate, defined as the proportion of subjects with BOR responses of CR or PR; Disease Control Rate, defined as the proportion of subjects with BOR responses of CR, PR or SD; Progression-Free Survival (or PFS), defined as time from first dose to either progressive disease, initiation of subsequent off-study therapy, or death	Screening (within 30 days prior to Day 1), Every 8 weeks, End of Treatment or 30-Day follow-up visits (approximately 18 months)	No

External Links

•   BMS clinical trial educational resource
•   BMS Clinical Trial Information
•   FDA Safety Alerts and Recalls
•   Investigator Inquiry form